BioMarin Pharmaceutical Inc. (LON:0HNC)
London · Delayed Price · Currency is GBP · Price in USD 53.91
+0.90 (1.70%)
At close: Sep 16, 2025
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,040 employees as of December 31, 2024. The number of employees decreased by 361 or -10.61% compared to the previous year.
Employees
3,040
Change (1Y)
-361
Growth (1Y)
-10.61%
Revenue / Employee
735.57K GBP
Profits / Employee
157.80K GBP
Market Cap
7.64B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3,040 | -361 | -10.61% |
| Dec 31, 2023 | 3,401 | 319 | 10.35% |
| Dec 31, 2022 | 3,082 | 37 | 1.22% |
| Dec 31, 2021 | 3,045 | -14 | -0.46% |
| Dec 31, 2020 | 3,059 | 58 | 1.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
BioMarin Pharmaceutical News
- 8 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga
- 9 days ago - PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga
- 9 days ago - BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for ... - GuruFocus
- 10 days ago - BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting - PRNewsWire
- 10 days ago - BioMarin Pharmaceutical (BMRN) Sees New Coverage with Neutral Rating | BMRN Stock News - GuruFocus
- 10 days ago - BioMarin (BMRN) Releases Promising PALYNZIQ Study Results for PKU Treatment - GuruFocus
- 11 days ago - BioMarin Pharmaceutical Inc (BMRN) Reveals Promising Phase 3 PEGASUS Study Results for PALYNZIQ ... - GuruFocus